Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACADEMIC: Abiraterone vs Docetaxel in mHSPC
NCT03827473Phase 2Terminated
- Sponsor
- University of Utah
- Start
- Feb 2019
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in prostate cancer (PCa) comparing ADT + Docetaxel with ADT + Abiraterone (2 arms). Primary endpoint: Change in Quality of Life - FACT-P at 12 months. Started Feb 2019; status: terminated.
02
Drugs
Abiraterone Acetate Tablets (I)docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03827473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03827473.